Status:
COMPLETED
Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
Lead Sponsor:
Nantes University Hospital
Conditions:
Von Willebrand Disease
Eligibility:
All Genders
18+ years
Brief Summary
Von Willebrand Disease (VWD) is defined as an inherited bleeding disorder that is caused by deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates the initial adhesio...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient with bleeding history sent to the Hemophilia Treatment Center in Dijon or Nantes University Hospital with abnormal bleeding score (\>3 in men and \>5 in women
- Patient who has provided a signed consent to participate at this study and for blood sampling
- Affiliation with French social security system
- Non-Inclusion Criteria:
- Minors will not be included in the study.
- On-going pregnancy and postpartum period (3 months after delivery)
- Substitutive treatment with coagulation factor concentrates or desmopressin administration within 10 days before sampling.
- Ongoing infectious or inflammatory disease that can modify VWF levels.
- Diagnosis of obvious hemostasis disorder
Exclusion
Key Trial Info
Start Date :
February 22 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT02792205
Start Date
February 22 2017
End Date
June 30 2021
Last Update
June 10 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dijon University Hospital
Dijon, France, 21079
2
Nantes University Hospital
Nantes, France, 44093